title: Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits.
abstract: BACKGROUND
  Prospective epidemiological studies support the hypothesis that high levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I limit atherosclerosis development. However, more data from studies with animal models of atherosclerosis that resemble the human disease are required to demonstrate the effect of apo A-I in the inhibition of atherogenesis. The rabbit is a good animal model for human atherosclerosis.
  
  
  RESULTS
  Human apo A-I-transgenic rabbits have been produced, and we have evaluated the effect of apo A-I on the development of atherosclerosis in transgenic rabbits fed a cholesterol-rich diet for 14 weeks. Plasma cholesterol levels of atherogenic apo B-containing lipoproteins were similar for transgenic and control rabbits (> 1000 mg/dL), while plasma levels of HDL cholesterol in the transgenic group were always about twice that of the control group (68 +/- 11 versus 37 +/- 3 mg/dL at 14 weeks; P < .001). At the end of the experiment, the amount of aortic surface area covered by lesions as well as the amount of lipid accumulation in the aorta were significantly less in transgenic rabbits compared with the control group (15 +/- 12% versus 30 +/- 8%, P < .0027 for the surface area of the thoracic aorta; 116 +/- 31 versus 247 +/- 39 mumol/g aorta, P < .0068 for cholesterol content in total aorta).
  
  
  CONCLUSIONS
  Overexpression of human apo A-I in rabbits inhibits the development of atherosclerosis in this animal model that resembles, in many respects, human atherosclerosis.
authors.affiliation: Rhône-Poulene Rorer-Gencell division, Atherosclerosis Department, Centre de Recherebe de Vitry-Alfortville, Vitry sor Seine, France. nicolas.duverger@rp.fr
authors.forename: N
authors.initials: N
authors.lastname: Duverger
authors.forename: H
authors.initials: H
authors.lastname: Kruth
authors.forename: F
authors.initials: F
authors.lastname: Emmanuel
authors.forename: J M
authors.initials: JM
authors.lastname: Caillaud
authors.forename: C
authors.initials: C
authors.lastname: Viglietta
authors.forename: G
authors.initials: G
authors.lastname: Castro
authors.forename: A
authors.initials: A
authors.lastname: Tailleux
authors.forename: C
authors.initials: C
authors.lastname: Fievet
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: L M
authors.initials: LM
authors.lastname: Houdebine
authors.forename: P
authors.initials: P
authors.lastname: Denefle
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D030801:Animals, Genetically Modified; D001011:Aorta / Q000737:chemistry / Q000378:metabolism; D016632:Apolipoprotein A-I / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D001053:Apolipoproteins / Q000097:blood*; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology* / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D002791:Cholesterol, Dietary; D004036:Diet, Atherogenic; D006801:Humans; D008114:Liver Neoplasms, Experimental; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D012016:Reference Values
chemical_list: D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D002791:Cholesterol, Dietary; D002784:Cholesterol